文献速递免疫规划卫生政策与健康促进

HPV预防性疫苗的免疫原性:血清学检测及其在HPV疫苗评价与研发中的应用

Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.
PubMed 文献 · Vaccine · 2018-02-01

本文总结已上市HPV预防性疫苗的免疫原性及常用血清学检测方法,重点讨论一剂次接种方案的考量。两剂次(间隔6个月)抗体反应非劣效证据支持WHO近期推荐的9-14岁男孩和女孩两剂次接种方案;一剂次疫苗可能有类似保护但缺乏稳健的效力和免疫原性数据。不同研究间免疫原性检测方法不同妨碍直接比较,标准化检测与报告对当前疫苗覆盖的多达9种HPV型别至关重要。

要点

  • 已上市HPV疫苗按标准三剂次接种显示卓越免疫原性和效力。
  • 两剂次(间隔6个月)抗体反应非劣效证据支持WHO推荐9-14岁男孩女孩两剂次方案。
  • 一剂次疫苗可能有类似保护但缺乏稳健效力和免疫原性数据,需标准化检测与报告。

核心结论

  • 已上市HPV预防性疫苗按标准三剂次接种显示卓越免疫原性和效力,中和抗体被认为是主要保护机制。
  • 两剂次(间隔6个月)抗体反应非劣效证据支持WHO近期推荐的9-14岁男孩和女孩两剂次接种方案。
  • 一剂次HPV疫苗可能有类似当前推荐两剂次方案的保护,但缺乏稳健的效力和免疫原性数据。
  • 不同研究采用不同方法评估和报告免疫原性,妨碍不同研究和疫苗间结果直接比较。
  • 标准化检测和报告当前疫苗覆盖的多达9种HPV型别的免疫原性现已至关重要。

研究设计与样本

  • 本文为综述,总结已上市HPV预防性疫苗的免疫原性及最常用血清学检测方法,重点讨论一剂次接种方案的关键考量。

主要发现

  • 临床前和临床证据均指向中和抗体作为主要保护机制,尽管抗感染免疫保护关联尚未完全明确。
  • 两剂次(间隔6个月)HPV疫苗抗体反应非劣效性已得到证明。
  • 有证据提示一剂次HPV疫苗可能提供类似当前推荐两剂次方案的保护,但缺乏稳健的效力和免疫原性数据。
  • 新的头对头疫苗试验正在评估一剂次免疫原性和效力,预计依赖免疫桥接的试验数量将增加。
  • 在WHO HPV LabNet于2006年发起的HPV血清学检测标准化和协调工作基础上,将作为新合作的一部分生成新的二级标准品、关键参考试剂和检测指南。

关键数值与推荐

  • 两剂次(间隔6个月)HPV疫苗抗体反应非劣效性已得到证明,支持WHO近期推荐的9-14岁男孩和女孩两剂次接种方案。
  • 当前疫苗覆盖多达9种HPV型别,其免疫原性标准化检测和报告至关重要。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 抗感染免疫保护关联尚未完全明确。
  • 一剂次疫苗方案的效力和免疫原性稳健数据缺乏。
  • 不同研究采用不同方法评估和报告免疫原性,妨碍不同研究和疫苗间结果直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

When administered as standard three-dose schedules, the licensed HPV prophylactic vaccines have demonstrated extraordinary immunogenicity and efficacy. We summarize the immunogenicity of these licensed vaccines and the most commonly used serology assays, with a focus on key considerations for one-dose vaccine schedules. Although immune correlates of protection against infection are not entirely clear, both preclinical and clinical evidence point to neutralizing antibodies as the principal mechanism of protection. Thus, immunogenicity assessments in vaccine trials have focused on measurements of antibody responses to the vaccine. Non-inferiority of antibody responses after two doses of HPV vaccines separated by 6 months has been demonstrated and this evidence supported the recent WHO recommendations for two-dose vaccination schedules in both boys and girls 9-14 years of age. There is also some evidence suggesting that one dose of HPV vaccines may provide protection similar to the currently recommended two-dose regimens but robust data on efficacy and immunogenicity of one-dose vaccine schedules are lacking. In addition, immunogenicity has been assessed and reported using different methods, precluding direct comparison of results between different studies and vaccines. New head-to-head vaccine trials evaluating one-dose immunogenicity and efficacy have been initiated and an increase in the number of trials relying on immunobridging is anticipated. Therefore, standardized measurement and reporting of immunogenicity for the up to nine HPV types targeted by the current vaccines is now critical. Building on previous HPV serology assay standardization and harmonization efforts initiated by the WHO HPV LabNet in 2006, new secondary standards, critical reference reagents and testing guidelines will be generated as part of a new partnership to facilitate harmonization of the immunogenicity testing in new HPV vaccine trials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pinto LA, Dillner J, Beddows S, et al. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine. 2018. PMID: 29361344. doi:10.1016/j.vaccine.2017.11.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。